GLP-1 receptor agonist use rose 587%: implications for oral health

A recent PubMed review published in Clinical Oral Investigations reports a 587% increase in GLP-1 receptor agonist prescriptions for obesity between 2019 and 2024, underscoring their metabolic benefits. However, the study highlights emerging concerns of xerostomia, altered salivary flow, and potential caries risk that warrant regular oral monitoring. BDS practitioners should counsel patients on enhanced hygiene protocols when managing GLP-1RA users.